RemeGen Co. Ltd. Class A
688331
주식 순위
#2421
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
주가
$14.49
시가총액
$8.11B
변동 (1일)
2.99%
변동 (1년)
9.18%
국가
CN
거래 RemeGen Co. Ltd. Class A (688331)
카테고리
Healthcare
RemeGen Co. Ltd. Class A (688331)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 6.73
RemeGen Co. Ltd. Class A의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 6.73입니다. 2023년 말 기준 P/B 비율은 9.58였습니다.
RemeGen Co. Ltd. Class A의 P/B 비율 기록 (2018 ~ 2026)
매년 말 P/B 비율
| 연도 | P/B 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 6.73 | -17.42% |
| 2024 | 8.15 | -14.93% |
| 2023 | 9.58 | 16.11% |
| 2022 | 8.25 | 42.80% |
| 2021 | 5.78 | 24.56% |
| 2020 | 4.64 | -105.51% |
| 2019 | -84.22 | 114.76% |
| 2018 | -39.22 | 0.00% |
유사 기업 또는 경쟁사의 P/B 비율
| 회사 | P/B 비율 | P/B 비율 차이 | 국가 |
|---|---|---|---|
| 6.251 | -7.12% |
US
|
|
| 13.2547 | 96.95% |
US
|
|
| 4.208 | -37.47% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -8.14% |
NL
|
